Search Bar & Filters
Found 91 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a study drug called LY4065967 for treating chronic low back pain CLBP. This trial is part of a larger master protocol aimed at speeding up the development of new treatments for chronic pain conditions. The study focuses on adults with a history of low back pain lasting at least three months. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study uses a double-blind design, meaning neither the participants nor the researchers know who receives the study drug or placebo. The treatment phase lasts for 8 weeks, during which participants take the assigned medication regularly. During the study, participants will be assessed at the start and at week 8 for changes in pain intensity using a numeric rating scale. Other evaluations include overall improvement, worst pain intensity, sleep quality, emotional functioning, use of rescue medication, and disability related to back pain. The trial includes safety monitoring and will continue until April 2027, with visits scheduled to track these outcomes.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the drug LY4065967 for treating diabetic peripheral neuropathic pain DPNP. This study is part of a larger chronic pain master protocol aimed at speeding up the development of new treatments for chronic pain conditions. Participants have diabetes and suffer from symmetrical nerve pain in their lower limbs. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study is double-blinded, meaning neither participants nor researchers know who receives which treatment. The treatment phase will last 8 weeks, during which pain and related symptoms will be monitored and compared between the groups. During the study, participants will have their pain intensity measured using a numeric rating scale at the start and at week 8. Other assessments include pain interference, overall improvement, sleep quality, emotional functioning, and daily use of rescue medication. The study involves regular monitoring to evaluate these outcomes and ensure participant safety throughout the 8-week treatment period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the drug LY4065967 for treating knee pain caused by osteoarthritis. This study is part of a larger effort called the chronic pain master protocol to speed up the development of new treatments for chronic pain conditions. The trial is a randomized, placebo-controlled Phase 2 study focusing on adults with knee osteoarthritis pain lasting more than 12 weeks. Participants will be randomly assigned to receive either LY4065967 or a placebo, both administered orally. The study compares these two groups to assess how well LY4065967 works in reducing knee pain and improving related symptoms. Treatment effects will be measured over an 8-week period, with evaluations at the start and end of this timeframe. During the study, participants will undergo regular assessments including pain intensity ratings using the Numeric Rating Scale, evaluations of arthritis symptoms, sleep quality, emotional functioning, and use of any rescue medication. Researchers will monitor the safety and effectiveness of the treatment through these measures. The total study duration for participants is approximately 8 weeks, with monitoring at baseline and week 8 to observe changes from the start of treatment.
Actively Recruiting
Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are conducting a master protocol study to evaluate multiple independent pain interventions for chronic pain conditions, including osteoarthritis of the knee, chronic low back pain, and diabetic peripheral neuropathic pain. This phase 2, randomized, placebo-controlled trial aims to establish a framework for disease-state addenda and intervention-specific appendices to efficiently study different treatments as they become available. Participants are randomly assigned to receive one of several investigational drugs or a matching placebo. These drugs include LY3016859 administered intravenously and LY3556050, LY3526318, LY3857210, and LY4065967 administered orally. Each intervention-specific appendix operates independently within the overarching study structure, allowing evaluation of various treatments targeting different chronic pain conditions. During the study, participants undergo screening and are monitored for pain levels using specific scales. They maintain consistent use of non-drug pain therapies and discontinue other chronic pain medications except rescue medication. Researchers measure participant allocation to each intervention up to week 8. Safety is monitored through physical exams, ECGs, laboratory tests, and medical history assessments. The study is expected to be completed by April 2027.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are evaluating the drug brenipatide compared to a placebo to see if it works and is safe for adults with Alcohol Use Disorder AUD and hazardous alcohol use. This phase 3 study aims to understand how brenipatide affects drinking patterns over time. Participation in this trial will last about 56 weeks, with careful monitoring throughout. Participants will receive brenipatide or placebo through subcutaneous injections. The study includes escalating doses of brenipatide administered under the skin. Participants must self-inject the study drug or receive assistance from a trained support person if needed. The treatment phase is structured in parallel groups, comparing the drug against placebo. During the study, participants will attend regular visits and be asked to maintain study diaries and complete questionnaires. Researchers will assess changes in drinking patterns using the Timeline Followback Method, daily alcohol consumption, alcohol cravings, and health outcomes such as body weight and quality of life. Blood samples will be collected to measure brenipatide levels and monitor for any immune responses. The study includes safety monitoring and lasts for approximately 56 weeks.
1-10 of 91
1